Physician profile
Weldon R Johnson
NPI 1063462331
$2,315.89
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $636 · 2021: $678 · 2022: $29.46 · 2023: $22.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $291.36 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $262.17 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $241.02 | 2019-2021 | |
| Abbvie INC. | $180.25 | 2020-2023 | |
| Genentech USA, INC. | $167.70 | 2019-2021 | |
| Amarin Pharma, INC. | $162.78 | 2019-2021 | |
| Pfizer INC. | $146.96 | 2019-2020 | |
| Lilly USA, LLC | $119.91 | 2020-2021 | |
| Novo Nordisk INC | $66.28 | 2021 | |
| Amgen INC. | $55.76 | 2019-2020 | |
| Allergan, INC. | $42.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $40.78 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.69 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $34.11 | 2019 | |
| Antares Pharma, INC. | $31.15 | 2020-2021 | |
| Horizon Therapeutics Plc | $27.80 | 2019-2020 | |
| Eisai INC. | $18.85 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.18 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.75 | 2021 | |
| Sanofi Pasteur INC. | $14.29 | 2019 | |
| Aytu Biopharma, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weldon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.